Paper Details

  1. Home
  2. Paper Details

Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.

Author: BhadoriaAjeet S, BulterysMarc, CuiFuqiang, EasterbrookPhilippa, FordNathan, HanQin, HutinYvan, LuYing, TanAlex, TanMingjuan, Van HoltenJudith

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Only a small proportion of the estimated 257 million people living with chronic hepatitis B virus (HBV) infection worldwide are diagnosed and treated. The study aimed to estimate the proportion of people with chronic HBV infection who are eligible for antiviral treatment worldwide, based on WHO guidelines.
Paper Details　
Original Abstract of the Article :
In 2016, of the estimated 257 million people living with chronic hepatitis B virus (HBV) infection worldwide, only a small proportion was diagnosed and treated. The insufficiency of information on the proportion of people infected with HBV who are eligible for treatment limits the interpretation of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801814/

データ提供：米国国立医学図書館（NLM）

Global Hepatitis B: Mapping the Landscape of Treatment

The [global burden of chronic hepatitis B virus (HBV) infection] is a significant public health concern. This study, like a meticulous cartographer, seeks to map the landscape of HBV treatment eligibility worldwide. The goal is to determine what proportion of people with chronic HBV infection are eligible for antiviral treatment, based on the [WHO 2015 guidelines]. By understanding this landscape, we can optimize treatment efforts and ensure that the right individuals receive the care they need.

A Global Snapshot of HBV Treatment Eligibility

The study's findings reveal that [only a small proportion of people living with chronic HBV infection are diagnosed and treated]. This is similar to a desert that is vast and unexplored, with only a few oases providing respite. The study also highlights the [insufficient information on the proportion of people infected with HBV who are eligible for treatment], making it challenging to assess the effectiveness of global treatment coverage.

Hepatitis B Treatment: A Call for Action

The study serves as a call to action, emphasizing the need to [increase diagnosis and treatment] for HBV infection worldwide. Much like a desert traveller seeking a source of water, individuals living with HBV need access to appropriate care and support. We must work collaboratively to ensure that everyone has a fair chance to access the treatments they need, transforming the desert landscape of HBV into a more verdant and hopeful one.

Dr.Camel's Conclusion

This study highlights the critical need to improve global hepatitis B treatment coverage. By accurately assessing treatment eligibility, we can ensure that individuals with HBV receive the necessary care. This research serves as a map for future efforts to address the global burden of HBV, paving the way for a healthier future.

Date :
  1. Date Completed 2021-02-18
  2. Date Revised 2021-02-27
Further Info :

Pubmed ID

33197397

DOI: Digital Object Identifier

PMC7801814

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.